Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid. (Clinical Oncology News, free registration required)
https://www.medpagetoday.com/hematologyoncology/othercancers/69201
Docetaxel-Based Chemo Ups Survival in Gastric Cancer